Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C
Open Access
- 30 October 2015
- journal article
- research article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 30 (6) , 792-800
Abstract
Thyroid dysfunction (TD) is more likely to occur in patients with chronic hepatitis C (CHC) and is particularly associated with interferon (IFN) treatment. The purpose of this study was to investigate the incidence, outcomes, and risk factors for TD during pegylated interferon (PEG-IFN) and ribavirin (RBV) combined therapy in patients with CHC. A total of 242 euthyroid patients with CHC treated with PEG-IFN/RBV were included. Thyroid function and autoantibodies were measured at baseline, and virologic response and thyroid function were assessed every 3 months during therapy. TD developed in 67 patients (27.7%) during the PEG-IFN/RBV treatment. The types of TD were subclinical hypothyroidism (50.7%), hypothyroidism (14.9%), thyroiditis (11.9%), subclinical hyperthyroidism (10.4%), and hyperthyroidism (10.4%). Most of the patients with TD recovered spontaneously; however, seven patients (10.4%) needed thyroid treatment. The sustained virological response rate was higher in patients with TD than those without (65.7% vs. 49.1%, p = 0.02). Baseline thyroid stimulating hormone (TSH) concentrations (odds ratio [OR], 2.09; 95% confidence interval [CI], 1.96 to 8.77; p < 0.001), presence of the thyroid peroxidase antibody (OR, 8.81; 95% CI, 1.74 to 44.6; p = 0.009), and PEG-IFNα-2b (OR, 3.01; 95% CI, 1.43 to 6.39; p = 0.004) were independent risk factors for the development of TD. TD developed in 27.7% of patients with CHC during PEG-IFN/RBV treatment, and 10.4% of these patients needed thyroid treatment. TD is associated with a favorable virologic response to PEG-IFN/RBV. Assessment of TSH and thyroid autoantibodies at baseline and close monitoring of thyroid function during PEG-IFN/RBV therapy are necessary for early detection and management of IFN-induced TD.Keywords
This publication has 25 references indexed in Scilit:
- Thyroid dysfunction in a UK hepatitis C population treated with interferon‐α and ribavirin combination therapyClinical Endocrinology, 2010
- Thyroid dysfunction in patients with hepatitis C on IFN-α therapyNature Reviews Gastroenterology & Hepatology, 2009
- Development of thyroid diseases in the treatment of chronic hepatitis C with α-interferon may be a good prognosticator in achieving a sustained virological response: A meta-analysisJournal of Gastroenterology and Hepatology, 2009
- Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-α therapy for hepatitis C virus-related hepatitisEuropean Journal of Endocrinology, 2007
- Thyroid Disorders in Chronic Hepatitis C Virus InfectionThyroid®, 2006
- Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis.Journal of Gastroenterology and Hepatology, 2006
- Interferon-α and Autoimmune Thyroid DiseaseThyroid®, 2003
- Side effects of high-dose interferon therapy for chronic hepatitis CJournal of Hepatology, 1996
- The incidence of thyroid disorders in the community: a twenty‐year follow‐up of the Whickham SurveyClinical Endocrinology, 1995
- The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle‐aged women: associations with serum lipidsClinical Endocrinology, 1993